Thyroid tumorigenesis and molecular markers in thyroid cancer

Current Opinion in Oncology

Volumn 22, Issue 1, 2010, Pages 23-29

  Kouniavsky, Guennadi ^a,d   Zeiger, Martha A ^a,b,c  

^a Endocrine Surgery   (United States)

^b Oncology ^*  (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SHEBA MEDICAL CENTER   (Israel)

Author keywords

Alternative splicing; Gene rearrangement; Molecular abnormalities; Single nucleotide polymorphisms; Thyroid tumorigenesis

Indexed keywords

B RAF KINASE; BETA CATENIN; MICRORNA; MOLECULAR MARKER; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; RAS PROTEIN;

ALTERNATIVE RNA SPLICING; ANAPLASTIC CARCINOMA; ASPIRATION BIOPSY; CANCER DIAGNOSIS; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CLINICAL PRACTICE; EPIGENETICS; GENE EXPRESSION; GENE REARRANGEMENT; GENE SILENCING; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HUMAN; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; THYROID CANCER;

CELL TRANSFORMATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 73849134974     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328333846f     Document Type: Review

References (50)

1. Gudmundsson J, Sulem P, Gudbjartsson DF, et al. Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. Nat Genet 2009; 41:460-464.
2. He H, Nagy R, Liyanarachchi S, et al. A susceptibility locus for papillary thyroid carcinoma on chromosome 8q24. Cancer Res 2009; 69:625-631.
3. Jazdzewski K, Liyanarachchi S, Swierniak M, et al. Polymorphic mature microRNAs from passenger strand of premiR-146a contribute to thyroid cancer. Proc Natl Acad Sci U S A 2009; 106:1502-1505.
4. Penna-Martinez M, Ramos-Lopez E, Stern J, et al. Vitamin D receptor polymorphisms in differentiated thyroid carcinoma. Thyroid 2009; 19: 623-628.
5. Ho T, Li G, Lu J, et al. Association of XRCC1 polymorphisms and risk of differentiated thyroid carcinoma: a case-control analysis. Thyroid 2009; 19:129-135.
6. Chiang FY, Wu CW, Hsiao PJ, et al. Association between polymorphisms in DNA base excision repair genes XRCC1, APE1, and ADPRT and differentiated thyroid carcinoma. Clin Cancer Res 2008; 14:5919-5924.
7. Baida A, Akdi M, Gonzalez-Flores E, et al. Strong association of chromosome 1p12 loci with thyroid cancer susceptibility. Cancer Epidemiol Biomarkers Prev 2008; 17:1499-1504.
8. Dardano A, Falzoni S, Caraccio N, et al. 1513A>C polymorphism in the P2×7 receptor gene in patients with papillary thyroid cancer: correlation with histological variants and clinical parameters. J Clin Endocrinol Metab 2009; 94:695-698.
9. Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009; 94:2092-2098.
10. Gandhi MS, Stringer JR, Nikiforova MN, et al. Gene position within chromosome territories correlates with their involvement in distinct rearrangement types in thyroid cancer cells. Genes Chromosomes Cancer 2009; 48:222-228.
11. Guan H, Ji M, Hou P, et al. Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer. Cancer 2008; 113:247-255.
12. Huang Y, Prasad M, Lemon WJ, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A 2001; 98:15044-15049.
13. Huang Y, de la Chapelle A, Pellegata NS. Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma. Int J Cancer 2003; 104:735-744.
14. Ferrario C, Lavagni P, Gariboldi M, et al. Metallothionein 1G acts as an oncosuppressor in papillary thyroid carcinoma. Lab Invest 2008; 88:474-481.
15. Gujral TS, van Veelen W, Richardson DS, et al. A novel RET kinase-betacatenin signaling pathway contributes to tumorigenesis in thyroid carcinoma. Cancer Res 2008; 68:1338-1346.
16. Garcia-Rostan G, Camp RL, Herrero A, et al. Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 2001; 158:987-996.
17. Rocha AS, Soares P, Fonseca E, et al. E-cadherin loss rather than betacatenin alterations is a common feature of poorly differentiated thyroid carcinomas. Histopathology 2003; 42:580-587.
18. Lantsov D, Meirmanov S, Nakashima M, et al. Cyclin D1 overexpression in thyroid papillary microcarcinoma: its association with tumour size and aberrant beta-catenin expression. Histopathology 2005; 47:248-256.
19. Wang Y, Kowalski J, Tsai HL, et al. Differentiating alternative splice variant patterns of human telomerase reverse transcriptase in thyroid neoplasms. Thyroid 2008; 18:1055-1063.
20. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998; 26:3453-3459.
21. Marine JC, Francoz S, Maetens M, et al. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 2006; 13:927-934.
22. Marine JC, Dyer MA, Jochemsen AG. MDMX: from bench to bedside. J Cell Sci 2007; 120:371-378.
23. Rallapalli R, Strachan G, Cho B, et al. A novel MDMX transcript expressed in a variety of transformed cell lines encodes a truncated protein with potent p53 repressive activity. J Biol Chem 1999; 274:8299-8308.
24. Bartel F, Schulz J, Bohnke A, et al. Significance of HDMX-S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis. Int J Cancer 2005; 117:469-475.
25. Prodosmo A, Giglio S, Moretti S, et al. Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties. J Mol Med 2008; 86:585-596.
26. Lohrum MA, Vousden KH. Regulation and function of the p53-related proteins: same family, different rules. Trends Cell Biol 2000; 10:197-202.
27. Frasca F, Vella V, Aloisi A, et al. p73 tumor-suppressor activity is impaired in human thyroid cancer. Cancer Res 2003; 63:5829-5837.
28. Ishimoto O, Kawahara C, Enjo K, et al. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res 2002; 62:636-641.
29. Dominguez G, Garcia JM, Pena C, et al. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol 2006; 24:805-815.
30. Vella V, Puppin C, Damante G, et al. DeltaNp73alpha inhibits PTEN expression in thyroid cancer cells. Int J Cancer 2009; 124:2539-2548.
31. Bruni P, Boccia A, Baldassarre G, et al. PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1. Oncogene 2000; 19:3146-3155.
32. Gimm O, Perren A, Weng LP, et al. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol 2000; 156:1693-1700.
33. Di Loreto C, Tell G, Pestrin M, et al. PTEN and Egr-1 expression in thyroid proliferative lesions. Cancer Lett 2005; 224:105-109.
34. He H, Jazdzewski K, Li W, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A 2005; 102:19075-19080.
35. Jazdzewski K, Murray EL, Franssila K, et al. Common SNP in premiR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A 2008; 105:7269-7274.
36. Talotta F, Cimmino A, Matarazzo MR, et al. An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation. Oncogene 2009; 28:73-84.
37. Prasad NB, Somervell H, Tufano RP, et al. Identification of genes differentially expressed in benign versus malignant thyroid tumors. Clin Cancer Res 2008; 14:3327-3337.
38. Wiseman SM, Melck A, Masoudi H, et al. Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis. Ann Surg Oncol 2008; 15:2811-2826. Tissue microarrays are used to examine a panel of known molecular markers in an attempt to define a better diagnostic tool for thyroid FNA.
39. Khoo ML, Ezzat S, Freeman JL, Asa SL. Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. J Clin Endocrinol Metab 2002; 87:1810-1813.
40. Ito Y, Yoshida H, Uruno T, et al. Survivin expression is significantly linked to the dedifferentiation of thyroid carcinoma. Oncol Rep 2003; 10:1337-1340.
41. Antonaci A, Consorti F, Mardente S, et al. Survivin and cyclin D1 are jointly expressed in thyroid papillary carcinoma and microcarcinoma. Oncology reports 2008; 20:63-67.
42. Ringel MD, Hayre N, Saito J, et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 2001; 61:6105-6111.
43. Miyakawa M, Tsushima T, Murakami H, et al. Increased expression of phosphorylated p70S6 kinase and Akt in papillary thyroid cancer tissues. Endocr J 2003; 50:77-83.
44. Vasko V, Saji M, Hardy E, et al. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet 2004; 41:161-170.
45. Kada F, Saji M, Ringel MD. Akt: a potential target for thyroid cancer therapy. Curr Drug Targets Immune Endocr Metabol Disord 2004; 4:181-185.
46. Hou P, Ji M, Xing M. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer 2008; 113:2440-2447.
47. Elliott DD, Sherman SI, Busaidy NL, et al. Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Hum Pathol 2008; 39:15-20.
48. Landriscina M, Piscazzi A, Fabiano A, et al. Targeting epidermal growth factor receptor 1 signaling in human thyroid-stimulating hormone-independent thyroid carcinoma FRO cells results in a more chemosensitive and less angiogenic phenotype. Thyroid 2009; 19:629-637.
49. Liu Z, Hou P, Ji M, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 2008; 93:3106-3116.
50. Friedman S, Lu M, Schultz A, et al. CD133+ anaplastic thyroid cancer cells initiate tumors in immunodeficient mice and are regulated by thyrotropin. PLoS One 2009; 4:e5395.